Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Heat/Phenol-Killed, E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3 (EMP 123) in Healthy Volunteers Followed by Subjects Allergic to Peanuts (CoFAR 1)

NCT00850668 is registered in ClinicalTrials.gov with Allertein Therapeutics, LLC as lead sponsor.

NCT NCT00850668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00850668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Heat/Phenol-Killed, E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3 (EMP 123) in Healthy Volunteers Followed by Subjects Allergic to Peanuts (CoFAR 1)
Lead sponsor
Allertein Therapeutics, LLC
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2009
Completion date
October 31, 2010
Enrollment
15 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

food hypersensitivity, hypersensitivity, immediate hypersensitivity, peanut hypersensitivity